AHCYL1

Across TCGA pan-cancer cohorts, AHCYL1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AHCYL1 data layer compared with 19 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AHCYL1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AHCYL1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where AHCYL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.399	0.196	.006	20	view →
CCRCC	DFS	Median	III,IV	0.865	0.514	.002	14	view →
LSCC	DFS	Median	II,III,IV	0.841	1.000	.007	5	view →
GBM	OS	Quartile	All	0.675	0.466	.014	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AHCYL1–PDAC (DFS)

Open the PDAC breakdown →